Promius Pharma, LLC announced the introduction of Zenatane (Isotretinoin) Capsules, a newly approved isotretinoin option for patients with severe, recalcitrant, nodular acne. Zenatane will be supported by The Promius Promise, a pharmacy service designed specifically to support Zenatane prescribers and patients. The program may help improve patient and physician experiences by increasing educational support and reducing eligible patient out-of-pocket expenses. The program is designed to assist with patient education about treatment requirements and deliver Zenatane within 24 hours to US locations, at a reduced, if not zero, out-of-pocket expense, for eligible patients. “We looked at the advantages and disadvantages of prescribing isotretinoin,” explained Rob D'Urso, head of sales and marketing at Promius Pharma, “and understood two paradoxical issues. The majority of dermatologists believe isotretinoin can make an enormous contribution to the quality of life of a patient with severe recalcitrant nodular acne. Yet, based on an FDA review of year 5 of the iPLEDGE program (3/1/10 – 2/28/11), over 400,000 attempts to fill isotretinoin prescriptions were denied due to failures to meet iPLEDGE requirements. We hope The Promius Promise can help.”